A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NCT ID: NCT06769659
Last Updated: 2025-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
10 participants
INTERVENTIONAL
2025-03-11
2026-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
NCT06525649
A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects
NCT01918735
A Study of GWP42006 in People With Focal Seizures - Part B
NCT02365610
A Study of GWP42006 in People With Focal Seizures - Part A
NCT02369471
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
NCT00567424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NPT 2042 80mg
NPT 2042 80mg BID
NPT 2042
NPT 2042 is a new drug being developed as an anti-seizure treatment
Placebo
Placebo Comparator
Placebo
Matching placebo for active comparator
NPT 2042
NPT 2042 is a new drug being developed as an anti-seizure treatment
Placebo
Placebo Comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NPT 2042
NPT 2042 is a new drug being developed as an anti-seizure treatment
Placebo
Placebo Comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is aged 16-75 years at the time of consent/assent
3. Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))
4. Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.
5. Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.
6. Subject has normal cognition and no clinically significant abnormalities on neurological examination at screening in the opinion of the Investigator
7. Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator, and as documented in the medical history, physical examination, and screening laboratory investigations
8. Subject has a body mass index (BMI) between 18 and 40 kg/m2 inclusive, at screening
9. Female subjects of child-bearing potential and all men agree to use of highly effective methods of contraception during the study and for 28 days after last dose of study drug
10. Subject (and parent/caregiver, if applicable) is able to communicate with the investigator and to understand and comply with all study requirements, including the clinic visit schedule
Exclusion Criteria
2. Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)
3. Subject has a history of convulsive status epilepticus within the past year.
4. Subject has a history of surgical intervention for treatment of epilepsy
5. Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)
6. Subject has severe intellectual disability, severe autism spectrum disorder, or severe developmental disorder such that the subject cannot consent or assent to participate or cannot cooperate with the study procedures
7. Female subject who is pregnant or lactating
8. Subject has any clinically significant laboratory abnormality which, in the opinion of the investigator, will exclude the subject from the study
9. Subject has an active CNS infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results
10. Subject has any clinically significant psychiatric illness, psychological or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study, including but not limited to the following:
1. Subject has active suicidal ideation prior to study entry as indicated by a positive response ("yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)
2. Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt)
11. Subject is suffering from clinically significant active liver disease, porphyria or has a family history of severe hepatic dysfunction indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT)
12. Subject has a DSM-V diagnosis of alcohol or drug abuse, or drug addiction within the past 12 months
13. Subject has participated in any other trials involving an investigational product or device within 30 days of screening or longer, as required by local regulations
14. Subject is currently using prohibited medications or products
15. Subject is unable to complete ingestion of four placebo SGCs with a minimum of eight ounces of water at screening
16. Subject (and parent/caregiver, if applicable) has daily commitments during the study duration that would interfere with attending all study visits
17. Positive urine drug test for substance of abuse or illegal recreational substances at screening
16 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NeuroPro Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trials, Inc. (CTI)
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NPT 2042 CL-200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.